Unicycive Therapeutics Inc (UNCY)

NASDAQ
0.73
0.00(0.00%)
  • Volume:
    17,512
  • Day's Range:
    0.71 - 0.73
  • 52 wk Range:
    0.51 - 2.35

UNCY Overview

Prev. Close
0.73
Day's Range
0.71-0.73
Revenue
951K
Open
0.73
52 wk Range
0.51-2.35
EPS
-1.03
Volume
17,512
Market Cap
10.84M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
26,813
P/E Ratio
-0.705
Beta
0.374
1-Year Change
-61.74%
Shares Outstanding
15,052,493
Next Earnings Date
Mar 30, 2023
What is your sentiment on Unicycive Therapeutics?
or
Vote to see community's results!

Unicycive Therapeutics Inc News

Unicycive Therapeutics Inc Company Profile

Unicycive Therapeutics Inc Company Profile

Employees
9

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Read More

Analyst Price Target

Average9.38 (+1,202.78% Upside)
High13.50
Low3.00
Price0.72
No. of Analysts3
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuySellSell
Technical IndicatorsBuyStrong BuyStrong BuyBuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell
  • So investing.com shows the neagative earnings news but not the positive coverage by Roth and price target of $13.50? I see whats going on here!
    0
    • Coverage initiaded by Roth Capital with $13.50 price tagert!!
      0
      • When we can buy it?
        0